Schizophrenia News

An interactive voice response system that uses artificial intelligence effectively monitored the well-being of patients with serious mental illness, according to study findings published in PLOS One.

Patients with psychiatric disorders are significantly more likely to be victimized by or perpetrators of violence than those without psychiatric disorders, according to findings of a nationwide cohort study published in JAMA Psychiatry.

An unmet need exists for care among young people with psychotic disorders, according to results of a population-based cohort study published in American Journal of Psychiatry. Researchers reported that incidence of psychotic experiences peaked during late adolescence.

Findings of a genome-wide association study published in JAMA Psychiatry suggest that many overlapping genetic risk variants exist between BMI and schizophrenia, bipolar disorder and major depression.

Results of a randomized clinical trial demonstrated a favorable safety profile and efficacy of lumateperone for patients with schizophrenia.

Patients with chronic schizophrenia who have acute exacerbations may not experience increased benefit from receiving antipsychotic doses higher than the identified 95% effective doses, according to results of a meta-analysis published in American Journal of Psychiatry.

Schizophrenia subgroups with distinct cognitive development trajectories can be determined using adult cognitive data, according to study findings published in American Journal of Psychiatry. Researchers noted that these subgroups have significantly different profiles of cognitive, academic and psychiatric genetic influence.

The FDA has approved Caplyta for the treatment of schizophrenia in adults, according to a press release from the agent’s manufacturer.

Individuals who were exposed to household pet dogs during infancy and childhood may have a decreased risk for developing schizophrenia, according to study findings published in PLoS One.

Alkermes recently announced submission of a new drug application to the FDA for its investigational schizophrenia treatment ALKS 3831, a combination of olanzapine and samidorphan, for the treatment of schizophrenia and the treatment of bipolar I disorder. If approved, the drug is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.